 |
|
LeadershipAdnexus is led by a leadership team with extensive industry experience covering all aspects of research, development, organizational development, partnering, and commercialization. Collectively, the team has previously played key roles in the development and commercialization of over 50 products.
John Edwards, President
Martin I. Freed, M.D., FACP, Chief Medical Officer
Eric Furfine, Ph.D., Senior Vice President of Research and Preclinical Development
Katrine Bosley, Vice President, Business Development
Erin Lanciani, Vice President, Human Resources
Alex Chu, Vice President, Manufacturing and Process Development
Ray Camphausen, Ph.D., Associate Vice President, Discovery
Kelledy Manson, Associate Vice President, Oncology Program Management
Bruce Silver, M.D., Medical Director
|
John Edwards was named President of Adnexus in October 2007. Prior to this, he served as our Chief Operating Officer from March 2005 until October 2007 and as our Vice President, Commercial Development from February 2004 through March 2005. From 2002 to 2004, Mr. Edwards served as Vice President, Sales, Marketing, and Medical Affairs at Transkaryotic Therapies, Inc., a biopharmaceutical company that was acquired by Shire plc in 2005. From 1987 to 2002, Mr. Edwards held senior-level R&D and Commercial positions at Genetics Institute, Inc., a biotechnology company. Following Wyeth Pharmaceuticals acquisition of Genetics Institute in 1996, he served as Associate Vice President, Global Strategic Marketing, with responsibility for managing the Oncology, Immunology, and Hematology therapeutic areas at Wyeth. Mr. Edwards received an M.B.A. from Boston University and a B.S. in Chemical Engineering from The University of Massachusetts at Amherst.
Martin Freed has served as our Chief Medical Officer since June 2007. From 2005 to 2007, Dr. Freed served as Chief Medical Officer at Vitae Pharmaceuticals, Inc., a pharmaceutical company. From 1991 to 2005, Dr. Freed held positions of increasing responsibility at GlaxoSmithKline, most recently as the Vice President, Clinical Development, North America. Dr. Freed received a M.D. from The Pennsylvania State University and a B.A. in Biology from the University of Delaware. Dr. Freed performed his internal medicine residency and nephrology post-doctoral training at Temple University Hospital and Yale New Haven Hospital, respectively. Dr. Freed has been board certified in Internal Medicine, Nephrology and Clinical Pharmacology.
Eric Furfine has served as our Senior Vice President, Research and Preclinical Development since August 2006. From 2002 to 2006, Dr. Furfine served as Vice President, Preclinical Development at Regeneron Pharmaceuticals Inc., a publicly-traded biotechnology company. From 1989 to 2002, Dr. Furfine held positions of increasing responsibility at GlaxoSmithKline, most recently as the Director of Biochemical and Analytical Pharmacology. Dr. Furfine received a Ph.D. in Biochemistry from Brandeis University and an A.B. in Chemistry from Washington University.
Katrine Bosley has served as our Vice President, Business Development since August 2004. From 1995 to 2004, Ms. Bosley held positions of increasing responsibility at Biogen Idec, Inc., a publicly-traded biopharmaceutical company, most recently as Director, Decision Support. From 1993 to 1995, Ms. Bosley served as an Analyst for Highland Capital Partners, a venture capital firm, and from 1991 to 1993, was at Alkermes, Inc. Ms. Bosley received a B.A. in Biology from Cornell University and completed the Program for Management Development at Harvard Business School.
Erin Lanciani has served as our Vice President, Human Resources since September 2006. From 2002 to 2006, Ms. Lanciani served as Vice President, Human Resources at Therion Biologics. From 2000 to 2001, Ms. Lanciani served as Director, Human Resources at ViaCell Inc., a biotechnology company. Ms. Lanciani holds a B.S. in Business Administration from Northeastern University.
Alex Chu has served as our Vice President, Manufacturing and Process Development since January 2007. From 2002 to 2007, Dr. Chu held positions of increasing responsibility at Abbott Bioresearch Center, part of Abbott Laboratories, a publicly-traded pharmaceutical company, most recently as Director, Manufacturing Program Management. From 1988-2001, Dr. Chu held positions of increasing responsibility at Abbott Laboratories, most recently as Department Manager, Chemical Research and Development. Dr. Chu holds a Ph.D. in biochemical engineering from the University of Wisconsin-Madison and a B.S. in chemical engineering from National Taiwan University.
Ray Camphausen has served as our Associate Vice President, Discovery since August 2006. Previously, Dr. Camphausen was Senior Director, Discovery from September 2005 through August 2006, and was hired as Director, Research in May 2003. From 2002 to 2003, Dr. Camphausen served as Vice President, Research and Discovery at Thios Pharmaceuticals, a biopharmaceutical company. From 1987 to 2002, Dr. Camphausen held positions of increasing responsibility at Genetics Institute and then at Wyeth Pharmaceuticals Inc. following its acquisition of Genetics Institute, most recently as Associate Director/Senior Scientist. Dr. Camphausen holds a Ph.D. in Microbiology from Colorado State University and a B.A. in Biology from the University of California, San Diego.
Kelledy Manson has served as our Associate Vice President, Oncology Program Management since January 2007. From 2001 to 2006, Ms. Manson held positions of increasing responsibility at Therion Biologics Corporation, a biotechnology company, most recently as Senior Director Bioanalytical Development and Program Executive. From 2000 to 2001, Ms. Manson was Director, Preclinical Operations at AltaRex Corp., a biotechnology company. From 1992 to 2000, Ms. Manson held positions of increasing responsibility at Primedica Corporation, most recently as Director Laboratory Services and AIDS Research. Ms. Manson holds a M.S. in biology Worcester Polytechnic Institute and a B.S. in Medical Technology from Michigan State University.
Bruce Silver has served as our Medical Director since November 2006. From 2001 to 2006, Dr. Silver held positions of increasing responsibility at PRA International, a clinical development organization, most recently as Vice President, Oncology, Global Product Development Services. From 1999 to 2001, Dr. Silver was the Chairman, Department of Medicine and Member, Medical Executive Committee at Calvert Memorial Hospital. Dr. Silver holds a M.D. from the University of Maryland School of Medicine and a B.S. in Biology from the University of Maryland. Dr. Silver is a board certified internist and oncologist and practiced medical oncology, hematology and internal medicine for 20 years before transitioning to his current role in industry.